TipRanks on MSN

Terns Pharmaceuticals Halts TERN-601 Development

Terns Pharmaceuticals ( ($TERN) ) just unveiled an announcement. On October 21, 2025, Terns Pharmaceuticals announced the topline 12-week results ...

Terns Pharma shelves obesity drug after mid-stage trial disappoints

Terns Pharmaceuticals said on Tuesday it will stop developing its experimental obesity drug after data from a mid-stage trial showed modest weight loss and raised safety concerns. Shares of the ...
MarketWatch

Terns’s stock soars as analysts cheer leukemia data — and predict more gains

Terns Pharmaceuticals Inc.’s stock was soaring 14% Wednesday, as analysts cheered positive data released a day earlier on a treatment for chronic myeloid leukemia. The data from an early-stage trial ...
Nasdaq

Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

FOSTER CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small ...
MarketWatch

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Terns Pharmaceuticals Inc.’s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia. The Foster City, ...
BioSpace

Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile

Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN ...